Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lupe Duarte"'
Autor:
Ryotaro Nakamura, Corinna La Rosa, Dongyun Yang, Joshua A. Hill, Armin Rashidi, Hannah Choe, Qiao Zhou, Chetan Raj Lingaraju, Teodora Kaltcheva, Jeffrey Longmate, Jennifer Drake, Cynthia Slape, Lupe Duarte, Monzr M. Al Malki, Vinod A. Pullarkat, Ahmed Aribi, Steven Devine, Michael R. Verneris, Jeffrey S. Miller, Stephen J. Forman, Ibrahim Aldoss, Don J. Diamond
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/cf1ae355426e485785e84cba31e586c8
Autor:
Flavia Pichiorri, Ralf Buettner, Shu Tao, Stephen J. Forman, Michael Rosenzweig, Myo Htut, Amrita Krishnan, Tim Synold, Ni-Chun Tsai, Xiwei Wu, Arnab Chowdhury, Steven T. Rosen, Joycelynne Palmer, Samantha N. Hammond, Nitya Nathwani, James F. Sanchez, Lupe Duarte, Chatchada Karanes, Firoozeh Sahebi
Publikováno v:
Leuk Lymphoma
The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies. We conducted a phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a60b6e76ee50a37cd1103a31ec4194
https://doi.org/10.1080/10428194.2020.1742900
https://doi.org/10.1080/10428194.2020.1742900
Autor:
James F. Sanchez, Lupe Duarte, Shaji Kumar, Sagar Lonial, Jesus G. Berdeja, Firoozeh Sahebi, Joycelynne Palmer, Stephen J. Forman, Daniel Auclair, Prashant Kapoor, Michael Rosenzweig, Myo Htut, Amrita Krishnan, Chatchada Karanes, George Somlo, Ni Chun Tsai, Nitya Nathwani
Publikováno v:
Leukemia. 32:1567-1574
In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1dd902dd1903f9a0dc1b2f73ad5002
https://doi.org/10.1038/s41375-018-0038-8
https://doi.org/10.1038/s41375-018-0038-8
Autor:
Stephen J. Forman, Joshua A. Hill, Monzr M. Al Malki, Vinod Pullarkat, Qiao Zhou, Ryotaro Nakamura, Chetan Raj Lingaraju, Ibrahim Aldoss, Corinna La Rosa, Michael R. Verneris, Jeffrey Longmate, Thai Cao, Cynthia Slape, Lupe Duarte, Jennifer Drake, Jeffrey S. Miller, Ahmed Aribi, Dongyun Yang, Don J. Diamond, Steven M. Devine, Armin Rashidi, Hannah Choe
Publikováno v:
Blood. 138:2887-2887
Cytomegalovirus (CMV) infection remains a major cause of morbidity/mortality after allogeneic hematopoietic cell transplantation (HCT). Preemptive antiviral therapy is associated with drug-induced toxicities, and prophylactic therapy with letermovir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a13160dad2d4bf40a3d6ee514e6ceb
https://doi.org/10.1182/blood-2021-153312
https://doi.org/10.1182/blood-2021-153312
Autor:
Shaji Kumar, Mark A. Fiala, Morie A. Gertz, Ann Birgin, Keith Stockerl Goldstein, Francis K. Buadi, Joan Levy, Michelle Maharaj, Betsy LaPlant, Amrita Krishnan, Lupe Duarte, Kristina Laumann, Ravi Vij, Todd M. Zimmerman, Vivek Roy
Publikováno v:
American Journal of Hematology. 90:1106-1110
Bendamustine is a multifunctional alkylating agent with single agent activity in myeloma. We designed the current phase 1/2 trial to determine the maximum tolerated doses (MTD) of bendamustine that can be safely combined with lenalidomide and dexamet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048a600f30bbe33da626fbf8d084054a
https://doi.org/10.1002/ajh.24181
https://doi.org/10.1002/ajh.24181
Autor:
Lupe Duarte, Myo Htut, George Somlo, Michael Rosenzweig, Hari Parameswaran, Firoozeh Sahebi, Joshua Richter, Nitya Nathwani, Saurabh Chhabra, Tracy Stiller, Amrita Krishnan, Noa Biran, Chatchada Karanes
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:e71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5650b439dd95734f33e742aa8893f5aa
https://doi.org/10.1016/j.clml.2017.03.129
https://doi.org/10.1016/j.clml.2017.03.129
Autor:
Prashant Kapoor, Shaji Kumar, Firoozeh Sahebi, Joycelynne Palmer, Stephen J. Forman, Michael Rosenzweig, George Somlo, Lupe Duarte, Ni-Chun Tsai, James F. Sanchez, Amrita Krishnan, Chatchada Karanes, Sagar Lonial, Jesus G. Berdeja, Myo Htut, Nitya Nathwani
Publikováno v:
Blood. 128:3316-3316
Triplet regimens combining an immunomodulatory agent, a proteasome inhibitor (PI), and a steroid are used to treat newly diagnosed and relapsed multiple myeloma (MM). Although ixazomib (Ix), an oral PI with single agent activity, can be combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c7c79b1c73ee2094ec450a8726ed7aa
https://doi.org/10.1182/blood.v128.22.3316.3316
https://doi.org/10.1182/blood.v128.22.3316.3316
Autor:
Prashant Kapoor, Stephen J. Forman, Firoozeh Sahebi, Shaji Kumar, Myo Htut, Michael Rosenzweig, Lupe Duarte, Chatchada Karanes, Jesus G. Berdeja, Nitya Nathwani, Sagar Lonial, Joycelynne Palmer, Amrita Krishnan, George Somlo
Publikováno v:
Journal of Clinical Oncology. 34:8008-8008
8008Background: Triplet regimens combining an immunomodulatory agent, a proteasome inhibitor (PI) and steroid are used to treat newly diagnosed and relapsed MM. While Ix, an oral PI with single age...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db1be29709968332b6bc5b423f109f5d
https://doi.org/10.1200/jco.2016.34.15_suppl.8008
https://doi.org/10.1200/jco.2016.34.15_suppl.8008
Autor:
Pablo M. Parker, Ji-Lian Cai, Amrita Krishnan, Stephen J. Forman, Firoozeh Sahebi, Ricardo Spielberger, Leslie Popplewell, Joyce Murata-Collins, Eunicia Reburiano, Sandra H. Thomas, Myo Htut, Neil Kogut, George Somlo, Lupe Duarte, Christopher Ruel, Chatchada Karanes, Len Farol, Paul Frankel
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(3)
We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1745487d3a05af7d16e2a5629608ff84
https://pubmed.ncbi.nlm.nih.gov/22198542
https://pubmed.ncbi.nlm.nih.gov/22198542
Autor:
Ricardo Spielberger, Pablo M. Parker, Amrita Krishnan, Laetitia Jeannet, Ghislaine Gallez-Hawkins, Joycelynne Palmer, Valerie Jimenez, Xiuli Li, Stephen J. Forman, John A. Zaia, Len Farol, Anne E. Franck, Xueli Liu, Eunicia Reburiano, Myo Htut, Firoozeh Sahebi, Chatchada Karanes, Lupe Duarte
Publikováno v:
Journal of Clinical Oncology. 30:8089-8089
8089 Background: Increased immune responses post autologous HCT may be of benefit in long term disease control. Responses may be mediated by NK cell function and possibly other alternate pathways, including costimulatory molecule pathways. This pilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2ca940fd78784774de9d7ce0d083f00
https://doi.org/10.1200/jco.2012.30.15_suppl.8089
https://doi.org/10.1200/jco.2012.30.15_suppl.8089